Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.

Antimicrobial agents and chemotherapy - 1 Jan 2003

Ince Dilek, Zhang Xiamei, Silver L Christine, Hooper David C

Abstract excerpt

Gemifloxacin, a novel quinolone with potent activity against Staphylococcus aureus, was 8- to 16-fold more active against wild-type S. aureus than ciprofloxacin. The two- to fourfold increase in the MIC of gemifloxacin in genetically defined grlBA mutants and the twofold increase in a single gyrA mutant, supported by the low frequency of selection of resistant mutants at twice the MIC (7.4 x 10(-11) to 1.1 x...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Drug Resistance, Bacterial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fluoroquinolones

Share to Microbial Sensitivity Tests

Share to Mutation

Share to Naphthyridines

Share to Plasmids

Share to Staphylococcus aureus

Source

Open in PubMed Open full text

Identifiers

PMID: 12499202
DOI: 10.1128/AAC.47.1.274-282.2003
PMCID: PMC149033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.PMID 12499202Read ↗

Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.Semantic proximity Read ↗

Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Semantic proximity Read ↗

Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Semantic proximity Read ↗

Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.Semantic proximity Read ↗

Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.Semantic proximity Read ↗

Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin.Semantic proximity Read ↗

Antibacterial Activity of Gatifloxacin (AM-1155, CG5501, BMS-206584), a Newly Developed Fluoroquinolone, against Sequentially Acquired Quinolone-Resistant Mutants and the norA Transformant of Staphylococcus aureusSemantic proximity Read ↗

Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolonesSemantic proximity Read ↗

Molecular characterization of 8-methoxyfluoroquinolone resistance in a clinical isolate of methicillin-resistant Staphylococcus aureus.Semantic proximity Read ↗

grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.Semantic proximity Read ↗

Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitorsSemantic proximity Read ↗

Topoisomerase IV is a target of quinolones in Escherichia coli.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.